MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Critical Care
Critical Care

Evaluating Ulinastatin for Sepsis: Insights from the ADJUST Trial

MedXY Editorial TeamNov 18, 2026
Mortalitysepsissafetyulinastatin

Highlight

  • The ADJUST trial evaluated intravenous ulinastatin in ICU patients with early sepsis.

  • Ulinastatin did not reduce 28-day all-cause mortality compared with placebo.

  • Secondary outcomes including longer-term mortality and length of stay showed no significant benefit.

  • Adverse events were notably higher in the ulinastatin group, raising safety concerns.

Study Background

Sepsis remains a major cause of morbidity and mortality in intensive care units worldwide. Despite advances in supportive care and infection control, mortality rates remain high. Therapeutic adjuncts that modulate the excessive inflammatory response characteristic of sepsis have been explored with varying success. Ulinastatin, a urinary trypsin inhibitor, has demonstrated anti-inflammatory and protease inhibitory effects in preclinical and some observational studies. However, robust randomized clinical trial evidence evaluating its efficacy in sepsis, especially by current definitions (Sepsis-3), has been lacking. The ADJUST trial was designed to address this unmet need by testing whether adjunctive ulinastatin reduces 28-day mortality in adult septic patients.

Study Design and Methods

The ADJUST study was a multicenter, randomized, double-blind, placebo-controlled trial enrolling adult intensive care unit patients diagnosed with sepsis according to Sepsis-3 criteria within 48 hours of ICU admission. Eligible patients were randomized 1:1 to receive either intravenous ulinastatin (400,000 IU every 8 hours) or placebo for up to 10 days in addition to standard sepsis care. Randomization was stratified by site and presence of septic shock to balance baseline severity.

The primary endpoint was all-cause mortality at 28 days post-randomization. Secondary endpoints included mortality at ICU discharge, hospital discharge, and 90 days, as well as ICU and hospital length of stay. Safety endpoints consisted of adverse event rates during the intervention.

Key Findings

A total of 347 patients were randomized; 340 received the assigned intervention and were analyzed for safety, while the intention-to-treat population comprised 335 patients after accounting for withdrawals (165 in the ulinastatin group, 170 in placebo).

At 28 days, mortality was virtually identical between groups: 23.6% (39/165) in the ulinastatin group versus 22.9% (39/170) in placebo (absolute difference 0.7%, 95% CI -8.4% to 9.7%, P=0.98). The hazard ratio for death was 1.03 (95% CI 0.66 to 1.61, P=0.90), indicating no mortality benefit from ulinastatin.

Secondary outcomes such as ICU, hospital, and 90-day mortality and length of stay were also comparable between groups, with no statistically significant differences observed.

However, safety analysis revealed that adverse events occurred more frequently in patients treated with ulinastatin compared with placebo: 56.8% vs 42.7%, representing an absolute difference of 14.1% (95% CI 3.6% to 24.6%, P=0.009). This increased risk of adverse events raises concerns about the overall benefit-risk profile of ulinastatin in this population.

Expert Commentary

The ADJUST trial provides the most rigorous evidence to date on ulinastatin’s role in sepsis treatment, showing it does not confer survival advantage and may increase complications. These findings contrast with some smaller or observational studies that suggested potential benefit, highlighting the importance of large-scale randomized trials.

Mechanistically, while ulinastatin modulates inflammatory proteases and cytokines, the complex and heterogeneous pathophysiology of sepsis may limit its efficacy when applied broadly. The stratification by septic shock in randomization strengthens the external validity, encompassing a representative ICU sepsis population.

Limitations include potential regional or care variability since conducted across multiple centers, and the fixed dosage not tailored to individual patient phenotypes. Further mechanistic studies could clarify subgroups who might derive benefit, but currently, clinical guidelines should not endorse routine ulinastatin use in sepsis management.

Conclusion

The multicenter ADJUST trial conclusively demonstrates that adjunctive ulinastatin does not reduce mortality in adult ICU patients with sepsis compared to placebo. Given the higher incidence of adverse events observed, routine clinical use of ulinastatin for sepsis cannot be recommended at this time. Future research should focus on targeted therapies guided by sepsis phenotyping and biomarkers rather than broad application of anti-inflammatory agents.

Funding and Trial Registration

The ADJUST trial was registered at ClinicalTrials.gov under NCT02647554. Details on funding sources were not specified in the abstract but are presumably disclosed in the full publication.

References

  • Chen Y, Jiang W, Yu X, et al. Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial. Chest. 2026 Nov 6. PMID: 42994751.

  • Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.

  • Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Evaluating NEWS-2 Guided Hour-1 Sepsis Bundle in Emergency Departments: Insights from the NEWS-1 TRIPS Pilot Trial

Critical CareNov 21, 2026

Refining Sepsis Time Zero: Identifying Organ Dysfunction Criteria that Impact Antibiotic Timing and Mortality Outcomes

Critical CareNov 21, 2026

Neutrophil:Lymphocyte Ratio After Sepsis Hospitalization: A Powerful Predictor of Long-Term Outcomes

Critical CareNov 18, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story